Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties

Author(s): Michele Caraglia, Alessandra Dicitore, Monica Marra, Sara Castiglioni, Luca Persani, Pasquale Sperlongano, Pierosandro Tagliaferri, Alberto Abbruzzese, Giovanni Vitale

Journal Name: Protein & Peptide Letters

Volume 20 , Issue 4 , 2013

Become EABM
Become Reviewer
Call for Editor


Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN- is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.

Keywords: Type I interferons, interferon-alpha, interferon-beta, STATs, mTOR, pegylated interferons, farnesyltransferase inhibitors, EGF-R, cytokine, antitumor activity

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 19 February, 2013
Page: [412 - 423]
Pages: 12
DOI: 10.2174/0929866511320040005

Article Metrics

PDF: 50